ABOUT US
Our Company
Our Team
Milestones
Awards
ESG
INNOVATION
Discoveries
Pipeline
Academic Research
PLATFORM
Innovation
Clinical Development
Commercialization
Manufacturing
INVESTORS
Overview
Finance & Announcements
Finance & Reports
Announcements
Corporate Communications
Pipeline
News & Events
Presentation Materials
Press Release
Event Calendar
Corporate Governance
Corporate Governance
ESG Reports
Stock Information
CAREERS
Core Values
Employee Experience
Job Opportunities
BUSINESS DEVELOPMENT
MEDIA
News
Media Reports
Public Announcements
CONTACT US
Strategic Footprint
Contact Information
中文
NEWS CENTER
News
News
Media Report
All
2026
2025
2024
2023
2022
2021
2020
2019
No data
Select
Empty
2026.11.11
InnoCare Announces First Patient Dosed in Clinical Trial of Novel PSMA/ STEAP1 Bispecific ADC ICP-B381 in China
Read
2026.11.09
InnoCare Announces First Patient Dosed in Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment Naive AML in China
Read
2026.11.05
2026 ASH Oral Presentation | InnoCare Announces Phase III Results of Orelabrutinib in ITP Study Meet Primary Endpoint
Read
2026.10.30
InnoCare Announces First Subject Dosed in Clinical Trial of TL1A/IL-23p19 Bispecific Antibody ICP-B161 in China
Read
2026.10.28
Latest Data of Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2026
Read
2026.10.26
InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization
Read
2026.10.16
Three Orelabrutinib Studies Presented in Oral Sessions at the 88th Annual Meeting of the Japanese Society of Hematology
Read
2026.10.13
InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed / Refractory MZL in China
Read
2026.10.12
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
Read
2026.09.24
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines
Read
2026.09.09
InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China
Read
2026.08.24
InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved
Read
common 235 Bar dynamics
1
2
3
4
5
6
20
ABOUT US
Our Company
Our Team
Milestones
Awards
ESG
INNOVATION
Discoveries
Pipeline
Academic Research
PLATFORM
Innovation
Clinical Development
Commercialization
Manufacturing
INVESTORS
Overview
Finance & Announcements
Pipeline
News & Events
Corporate Governance
Stock Information
CAREERS
Core Values
Employee Experience
Job Opportunities
BUSINESS DEVELOPMENT
MEDIA
News
Media Reports
Public Announcements
CONTACT US
Strategic Footprint
Contact Information
PRIVACY POLICY
© 2024 InnoCare. All Rights Reserved. |
京ICP备16037514号-5
|
京公网安备11011402010425号
药品医疗器械网络信息服务备案:
(京)网药械信息备字(2024)第00128号